Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Isis Pharmacueticals

Sanofi reception

Manufacturing issues scupper Sanofi’s sarilumab launch plans

FDA turns down the rheumatoid arthritis drug’s marketing application after routine inspection

Access to orphan drugs for rare cancers in EU28

Although the economic burden imposed by rare cancers has not yet been adequately assessed, the treatment burden posed by rare cancers on individuals, societies and healthcare systems make them a...

- PMLiVE

Access to orphan drugs for rare cancers in EU28

Although the economic burden imposed by rare cancers has not yet been adequately assessed, the treatment burden posed by rare cancers on individuals, societies and healthcare systems make them a...

- PMLiVE

Merck gets early OK for Keytruda in first-line lung cancer

FDA fast-tracks approval of PD-1/PD-L1 inhibitor for treatment of NSCLC

Bristol-Myers Squibb (BMS) building

Keytruda, Opdivo narrow Tecentriq’s lead in bladder cancer

BMS’ drug is currently under FDA and EMA review in advanced urothelial carcinoma

- PMLiVE

Roche creates the Fight IPF choir for disease awareness campaign

Aims to raise the lung disease's profile and inform patients and their families

Roche Basel Switzerland

Roche in “unprecedented” launch period for new medicines

Cotellic, Alecensa, Venclexta and Tecentriq position firm to meet 2016 sales targets

Roche Basel Switzerland

Lung cancer OK for Tecentriq sets up showdown with Merck and BMS

Broad label will aid Roche’s PD-L1 inhibitor in head-to-head NSCLC market-share battle

- PMLiVE

Mastering the rare disease challenge

Identifying expertise and customising communication in orphan drug marketing

- PMLiVE

CHMP backs Intercept’s rare liver disease drug

Ocaliva on track for EU approval as analysts predict blockbuster sales

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

National Institute for Health and Care Excellence NICE logo

NICE to create fast track for most cost-effective new drugs

Proposes accelerated appraisal process for drugs with QALY of £10,000 or less

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links